Adagio Medical Holdings Inc. (Nasdaq: ADGM) reported its financial results for the second quarter ended June 30, 2025. The company's cost of revenue decreased to $0.3 million from $0.7 million in the same period in 2024. Research and development expenses were reduced to $2.0 million from $2.9 million, while selling, general, and administrative expenses decreased to $2.4 million from $3.4 million compared to the previous year. The net loss for the quarter was $3.9 million, compared to a net loss of $5.7 million for the same period in 2024. Adagio reported cash and cash equivalents of $8.2 million as of June 30, 2025. Significant business highlights include surpassing 85% enrollment in the FULCRUM-VT pivotal study of the company's vCLAS™ Cryoablation System, which seeks to enroll 206 patients across 20 U.S. and Canadian centers and is on track for completion in the second half of 2025. Additionally, first-in-human results from the PARALELL study, evaluating the safety and effectiveness of Adagio's Pulsed Field Cryoablation, were published in the Journal of Cardiovascular Electrophysiology. The company also reported reduced cash burn quarter-over-quarter due to a corporate prioritization initiative aimed at streamlining operations and focusing resources on high-value programs.